Hypertension RDN Therapy - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510245581

Publication Date:

October 15, 2024

Pages:

115

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Renal denervation (also called renal ablation) is a minimally invasive, investigational procedure to treat hypertension (high blood pressure) that hasn't improved with other treatments. This type of hypertension is called resistant hypertension
The global market for Hypertension RDN Therapy was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Hypertension RDN Therapy was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Hypertension RDN Therapy was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Hypertension RDN Therapy was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Hypertension RDN Therapy include Medtronic, ReCor Medical, Sonivies, Covidien, Boston Scientific, Johnson & Johnson, Terumo Corporation, Angiocare and Shanghai Golden Leaf Med Tec, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hypertension RDN Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Hypertension RDN Therapy by region & country, by Type, and by Application.
The Hypertension RDN Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hypertension RDN Therapy.
麻豆原创 Segmentation
By Company
Medtronic
ReCor Medical
Sonivies
Covidien
Boston Scientific
Johnson & Johnson
Terumo Corporation
Angiocare
Shanghai Golden Leaf Med Tec
Shanghai Bio-Heart Biological Technology
Xinmai Medical Equipment
Microport Ep Medtech
Cryofocus Medtech
Segment by Type:
r-Renal Denervation(rRDN)
u-Renal Denervation(uRDN)
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Hypertension RDN Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Hypertension RDN Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Hypertension RDN Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Hypertension RDN Therapy Product Introduction
1.2 Global Hypertension RDN Therapy 麻豆原创 Size Forecast
1.3 Hypertension RDN Therapy 麻豆原创 Trends & Drivers
1.3.1 Hypertension RDN Therapy Industry Trends
1.3.2 Hypertension RDN Therapy 麻豆原创 Drivers & Opportunity
1.3.3 Hypertension RDN Therapy 麻豆原创 Challenges
1.3.4 Hypertension RDN Therapy 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Hypertension RDN Therapy Players Revenue Ranking (2023)
2.2 Global Hypertension RDN Therapy Revenue by Company (2019-2024)
2.3 Key Companies Hypertension RDN Therapy Manufacturing Base Distribution and Headquarters
2.4 Key Companies Hypertension RDN Therapy Product Offered
2.5 Key Companies Time to Begin Mass Production of Hypertension RDN Therapy
2.6 Hypertension RDN Therapy 麻豆原创 Competitive Analysis
2.6.1 Hypertension RDN Therapy 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Hypertension RDN Therapy Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypertension RDN Therapy as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 r-Renal Denervation(rRDN)
3.1.2 u-Renal Denervation(uRDN)
3.2 Global Hypertension RDN Therapy Sales Value by Type
3.2.1 Global Hypertension RDN Therapy Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Hypertension RDN Therapy Sales Value, by Type (2019-2030)
3.2.3 Global Hypertension RDN Therapy Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Hypertension RDN Therapy Sales Value by Application
4.2.1 Global Hypertension RDN Therapy Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Hypertension RDN Therapy Sales Value, by Application (2019-2030)
4.2.3 Global Hypertension RDN Therapy Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Hypertension RDN Therapy Sales Value by Region
5.1.1 Global Hypertension RDN Therapy Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Hypertension RDN Therapy Sales Value by Region (2019-2024)
5.1.3 Global Hypertension RDN Therapy Sales Value by Region (2025-2030)
5.1.4 Global Hypertension RDN Therapy Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Hypertension RDN Therapy Sales Value, 2019-2030
5.2.2 North America Hypertension RDN Therapy Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Hypertension RDN Therapy Sales Value, 2019-2030
5.3.2 Europe Hypertension RDN Therapy Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Hypertension RDN Therapy Sales Value, 2019-2030
5.4.2 Asia Pacific Hypertension RDN Therapy Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Hypertension RDN Therapy Sales Value, 2019-2030
5.5.2 South America Hypertension RDN Therapy Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Hypertension RDN Therapy Sales Value, 2019-2030
5.6.2 Middle East & Africa Hypertension RDN Therapy Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Hypertension RDN Therapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Hypertension RDN Therapy Sales Value
6.3 United States
6.3.1 United States Hypertension RDN Therapy Sales Value, 2019-2030
6.3.2 United States Hypertension RDN Therapy Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Hypertension RDN Therapy Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Hypertension RDN Therapy Sales Value, 2019-2030
6.4.2 Europe Hypertension RDN Therapy Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Hypertension RDN Therapy Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Hypertension RDN Therapy Sales Value, 2019-2030
6.5.2 China Hypertension RDN Therapy Sales Value by Type (%), 2023 VS 2030
6.5.3 China Hypertension RDN Therapy Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Hypertension RDN Therapy Sales Value, 2019-2030
6.6.2 Japan Hypertension RDN Therapy Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Hypertension RDN Therapy Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Hypertension RDN Therapy Sales Value, 2019-2030
6.7.2 South Korea Hypertension RDN Therapy Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Hypertension RDN Therapy Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Hypertension RDN Therapy Sales Value, 2019-2030
6.8.2 Southeast Asia Hypertension RDN Therapy Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Hypertension RDN Therapy Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Hypertension RDN Therapy Sales Value, 2019-2030
6.9.2 India Hypertension RDN Therapy Sales Value by Type (%), 2023 VS 2030
6.9.3 India Hypertension RDN Therapy Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Medtronic
7.1.1 Medtronic Profile
7.1.2 Medtronic Main Business
7.1.3 Medtronic Hypertension RDN Therapy Products, Services and Solutions
7.1.4 Medtronic Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.1.5 Medtronic Recent Developments
7.2 ReCor Medical
7.2.1 ReCor Medical Profile
7.2.2 ReCor Medical Main Business
7.2.3 ReCor Medical Hypertension RDN Therapy Products, Services and Solutions
7.2.4 ReCor Medical Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.2.5 ReCor Medical Recent Developments
7.3 Sonivies
7.3.1 Sonivies Profile
7.3.2 Sonivies Main Business
7.3.3 Sonivies Hypertension RDN Therapy Products, Services and Solutions
7.3.4 Sonivies Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.3.5 Covidien Recent Developments
7.4 Covidien
7.4.1 Covidien Profile
7.4.2 Covidien Main Business
7.4.3 Covidien Hypertension RDN Therapy Products, Services and Solutions
7.4.4 Covidien Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.4.5 Covidien Recent Developments
7.5 Boston Scientific
7.5.1 Boston Scientific Profile
7.5.2 Boston Scientific Main Business
7.5.3 Boston Scientific Hypertension RDN Therapy Products, Services and Solutions
7.5.4 Boston Scientific Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.5.5 Boston Scientific Recent Developments
7.6 Johnson & Johnson
7.6.1 Johnson & Johnson Profile
7.6.2 Johnson & Johnson Main Business
7.6.3 Johnson & Johnson Hypertension RDN Therapy Products, Services and Solutions
7.6.4 Johnson & Johnson Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.6.5 Johnson & Johnson Recent Developments
7.7 Terumo Corporation
7.7.1 Terumo Corporation Profile
7.7.2 Terumo Corporation Main Business
7.7.3 Terumo Corporation Hypertension RDN Therapy Products, Services and Solutions
7.7.4 Terumo Corporation Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.7.5 Terumo Corporation Recent Developments
7.8 Angiocare
7.8.1 Angiocare Profile
7.8.2 Angiocare Main Business
7.8.3 Angiocare Hypertension RDN Therapy Products, Services and Solutions
7.8.4 Angiocare Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.8.5 Angiocare Recent Developments
7.9 Shanghai Golden Leaf Med Tec
7.9.1 Shanghai Golden Leaf Med Tec Profile
7.9.2 Shanghai Golden Leaf Med Tec Main Business
7.9.3 Shanghai Golden Leaf Med Tec Hypertension RDN Therapy Products, Services and Solutions
7.9.4 Shanghai Golden Leaf Med Tec Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.9.5 Shanghai Golden Leaf Med Tec Recent Developments
7.10 Shanghai Bio-Heart Biological Technology
7.10.1 Shanghai Bio-Heart Biological Technology Profile
7.10.2 Shanghai Bio-Heart Biological Technology Main Business
7.10.3 Shanghai Bio-Heart Biological Technology Hypertension RDN Therapy Products, Services and Solutions
7.10.4 Shanghai Bio-Heart Biological Technology Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.10.5 Shanghai Bio-Heart Biological Technology Recent Developments
7.11 Xinmai Medical Equipment
7.11.1 Xinmai Medical Equipment Profile
7.11.2 Xinmai Medical Equipment Main Business
7.11.3 Xinmai Medical Equipment Hypertension RDN Therapy Products, Services and Solutions
7.11.4 Xinmai Medical Equipment Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.11.5 Xinmai Medical Equipment Recent Developments
7.12 Microport Ep Medtech
7.12.1 Microport Ep Medtech Profile
7.12.2 Microport Ep Medtech Main Business
7.12.3 Microport Ep Medtech Hypertension RDN Therapy Products, Services and Solutions
7.12.4 Microport Ep Medtech Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.12.5 Microport Ep Medtech Recent Developments
7.13 Cryofocus Medtech
7.13.1 Cryofocus Medtech Profile
7.13.2 Cryofocus Medtech Main Business
7.13.3 Cryofocus Medtech Hypertension RDN Therapy Products, Services and Solutions
7.13.4 Cryofocus Medtech Hypertension RDN Therapy Revenue (US$ Million) & (2019-2024)
7.13.5 Cryofocus Medtech Recent Developments
8 Industry Chain Analysis
8.1 Hypertension RDN Therapy Industrial Chain
8.2 Hypertension RDN Therapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Hypertension RDN Therapy Sales Model
8.5.2 Sales Channel
8.5.3 Hypertension RDN Therapy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Medtronic
ReCor Medical
Sonivies
Covidien
Boston Scientific
Johnson & Johnson
Terumo Corporation
Angiocare
Shanghai Golden Leaf Med Tec
Shanghai Bio-Heart Biological Technology
Xinmai Medical Equipment
Microport Ep Medtech
Cryofocus Medtech

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.